Titan Pharmaceuticals’ (NASDAQ:TTNP) CEO, Sunil Bhonsle, and Indegene VP of co-commercialization, Jamie Peck, provided additional information on their recently established Probuphine co-promotion partnership.
In an interview with pharmaexec.com, Mr. Bhonsle said that the company has had to find new ways to market its Probuphine implant for the long-term maintenance treatment of opioid use disorder (OUD), given the restrictions posed by the COVID-19 pandemic.
“With COVID-19 comes the increased use of telemedicine to provide medication-assisted treatment to OUD patients; accordingly, we are adapting our own business practices,” Mr. Bhonsle said in a statement.
Under the accord, Indegene will deliver multichannel marketing tools, predictive analytics, webinars and social media campaigns to help expand the number of Probuphine risk evaluation and mitigation strategy-certified health care providers.
“For a small pharmaceutical company, it makes perfect sense to partner with a company like Indegene and capitalize on their digital infrastructure to build long term virtual pathways for disseminating drug information and interacting with the medical community in this changing healthcare ecosystem,” he added.
Jamie Peck commented, “Post-COVID commercialization of products will require a different execution framework across a broad set of digital and other non-personal capabilities. This will be even more critical to the recovery as the incidence of OUD has become more acute over the past several months.”
